Merck Announces Filing of Form 10 Registration for Spinoff Organon & Co.

Goodwin
Contact

Goodwin

On March 17, 2021, Merck announced that it had filed a Form 10 registration statement with the U.S. Securities and Exchange Commission in order to spinoff its women’s health, biosimilars and established brands businesses into a standalone, publicly traded company, named Organon.  Merck explained that Organon’s vision is to “create a better and healthier every day for every woman around the globe.”  Merck also announced that Carrie Cox will serve as chairman of the majority-female Board, which will consist of many individuals having CEO experience and who represent the fields of medicine, public health, business and technology.  Carrie Cox explained, “[t]he representation of women on the Board — comprising 70% of positions — is higher than any S&P 500 healthcare company, focusing on Organon’s goal of making a positive impact on the global health of women.”

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.